Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness

Virchows Archiv

Volumn 446, Issue 6, 2005, Pages 589-595

  Trovisco, Vítor ^a   Soares, Paula ^a,b   Preto, Ana ^a   De Castro, Inês Vieira ^c   Lima, Jorge ^a   Castro, Patrícia ^a   Máximo, Valdemar ^a   Botelho, Tiago ^a   Moreira, Severina ^a   Meireles, Ana Margarida ^a   Magalhães, João ^d   Abrosimov, Alexander ^e   Cameselle Teijeiro, José ^f   Sobrinho Simões, Manuel ^a,b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^f Instituto de Salud Carlos III   (Spain)

Author keywords

BRAF; Follicular variant of PTC; Oncocytic variant; Oncogene; Papillary carcinoma; Thyroid

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; THYROID CARCINOMA; UTERINE CERVIX CARCINOMA; WARTHIN TUMOR;

ADENOCARCINOMA; ADULT; AGE FACTORS; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; SEX FACTORS; THYROID NEOPLASMS;

EID: 21544464303     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-1236-0     Document Type: Article

References (27)

1. Baloch ZW, LiVolsi VA (2002) Etiology and significance of the optically clear nucleus. Endocr Pathol 13:289-299
2. Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL (2002) Hurthle cell tumors: using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 128:237-240
3. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000
4. Castro P, Fonseca E, Magalhaes J, Sobrinlio-Simoes M (2002) Follicular, papillary, and "hybrid" carcinomas of the thyroid. Endocr Pathol 13:313-320
5. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL (2000) Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878-882
6. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818-821
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
10. Kumar R, Angelini S, Snellman E, Hemminki K (2004) BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-348
11. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4267-4271
12. LiVolsi V (1990) Surgical pathology of the thyroid. Saunders, Philadelphia
13. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397
14. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209:1-6
15. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
16. Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53-62
17. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F (2004) BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420
18. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/ RAS oncogenes and mismatch-repair status. Nature 418:934
19. Rosai J, Carcangiu ML, DeLellis RA (1992) Tumours of the thyroid gland. Armed Forces Institute of Pathology, Washington
20. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simoes M (1998) Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 185:71-78
21. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro, I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simoes M (2004) BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444:572-576
22. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580
23. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287-294
24. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247-251
25. Vickery AL Jr, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M (1985) Papillary carcinoma. Semin Diagn Pathol 2: 90-100
26. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567
27. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE (2003) Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77